Paper
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
Published Oct 1, 2004 · M. Camilleri, S. Mckinzie, J. Fox
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Q1 SJR score
119
Citations
4
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
RCT
Highly CitedStudy Snapshot
Renzapride significantly accelerates colon transit and improves bowel function in female patients with constipation-predominant irritable bowel syndrome.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Current concepts: Chronic constipation
Chronic constipation is a common issue affecting between 2% and 27% of the population in Western countries, with risk factors including physical inactivity, low income, limited education, sexual abuse history, and depression.
2003·623citations·A. Lembo et al.·The New England Journal of Medicine
The New England Journal of Medicine
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
Tegaserod 6 mg twice daily is an effective, safe, and well-tolerated treatment for irritable bowel syndrome in patients from the Asia-Pacific region without diarrhoea-associated symptoms.
2003·237citations·J. Kellow et al.·Gut
Gut
Neuronal location of 5-hydroxytryptamine3 receptor-like immunoreactivity in the rat colon
5-hydroxytryptamine 3 receptors are found on intrinsic sensory neurons in the rat colon and on extrinsic sensory nerve fibers that innervate the colon.
2003·31citations·Christophe Mazzia et al.·Neuroscience
Neuroscience
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
Both psychotherapy and paroxetine improve health-related quality of life for patients with severe irritable bowel syndrome at no additional cost.
2003·421citations·F. Creed et al.·Gastroenterology
Gastroenterology
AGA technical review on irritable bowel syndrome.
IBS is a common functional gastrointestinal disorder characterized by abdominal pain and disturbed defecation, and its psychosocial factors play a significant role in modulating the illness experience and clinical outcome.
2002·1423citations·D. Drossman et al.·Gastroenterology
Gastroenterology
Citations
Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract.
Scintigraphic colonic transit (CT) measurement is a reliable surrogate endpoint for symptom-based outcomes in irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC).
2025·0citations·Michael Camilleri et al.·Alimentary pharmacology & therapeutics
Alimentary pharmacology & therapeutics
Digestive Enzyme Activities and Gut Emptying Are Correlated with the Reciprocal Regulation of TRPA1 Ion Channel and Serotonin in the Gut of the Sea Urchin Strongylocentrotus intermedius
Sea urchins' low food digestibility is correlated with the relationship between TRPA1 and serotonin in their gut, providing valuable information on their digestive physiology.
2022·3citations·Jingyun Ding et al.·Biology
Biology
Association between SERT insertion/deletion polymorphism and the risk of irritable bowel syndrome: A meta-analysis based on 7039 subjects.
The SERT insertion/deletion polymorphism is a significant genetic biomarker for irritable bowel syndrome (IBS) risk in Asians and Caucasians, with a higher risk of constipation predominant IBS.
2018·29citations·Yubing Zhu et al.·Gene
Gene
DA‐9701 improves colonic transit time and symptoms in patients with functional constipation: A prospective study
DA-9701 improves colonic transit time and symptoms in patients with functional constipation, potentially enhancing gastrointestinal motor function.
2017·10citations·S. Y. Kim et al.·Journal of Gastroenterology and Hepatology
Journal of Gastroenterology and Hepatology
New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond
New therapeutic agents targeting low-grade inflammation, gut motility, secretion, and gut permeability show promise in treating irritable bowel syndrome.
2017·46citations·E. Sinagra et al.·World Journal of Gastroenterology
World Journal of Gastroenterology